NovaBridge Biosciences (NBP) — Cash Flow-to-Debt Ratio
NovaBridge Biosciences (NBP) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of $13.15 Million could theoretically repay 0% of its total liabilities ($131.67 Million) in one year. See NBP FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NovaBridge Biosciences Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for NovaBridge Biosciences across 8 annual periods. Also explore NovaBridge Biosciences net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NovaBridge Biosciences (2017–2024)
Year-by-year debt coverage analysis for NovaBridge Biosciences. For market capitalisation and broader financial context, see NovaBridge Biosciences (NBP) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.57x | $-52.65 Million | $11.52 Million | ▼ -5513.6% |
| 2023 | -0.08x | $-72.85 Million | $894.81 Million | ▲ +92.1% |
| 2022 | -1.04x | $-1.10 Billion | $1.07 Billion | ▼ -10.8% |
| 2021 | -0.93x | $-973.09 Million | $1.04 Billion | ▼ -252.3% |
| 2020 | 0.61x | $433.56 Million | $706.65 Million | ▲ +366.6% |
| 2019 | -0.23x | $-867.98 Million | $3.77 Billion | ▼ -173.0% |
| 2018 | -0.08x | $-280.70 Million | $3.33 Billion | ▲ +55.7% |
| 2017 | -0.19x | $-252.16 Million | $1.33 Billion | — |